Page 127 - InvUnivMult_2022

FACULTAD DE CIENCIA Y TECNOLOGÍA
Hammond J Leister-Tebbe H H Gardner A A Abreu P Bao W Wisemandle W W Baniecki M M Hendrick V M M Damle B Simón-Campos A Pypstra R R Rusnak J M y y EPIC- HR Investigators (2022) “Oral nirmatrelvir for high-risk nonhospitalized adults with Covid-19” En: The New England Journal of Medicine 386(15) 1397–1408 Consultado en: https://doi org/10 1056/NEJMoa2118542
He Y L (2012) “Clinical pharmacokinetics and pharmacodynamics of vildagliptin” En: Clinical Pharmacokinetics 51(3) 147– 162 Consultado en: https://doi org/10 2165/11598080- 000000000-00000
Heo Y A A (2022) “Sotrovimab: First Approval” En: Drugs 82(4) 477–484 Consultado en: https://doi org/10 1007/s40265- 022-01690-7
Herman G A A Stevens C Van Dyck K Bergman A A Yi B B De Smet M M Snyder K Hilliard D Tanen M M Tanaka W W Wang A Q Zeng W W Musson D D Winchell G Davies M M J Ramael S Gottesdiener K M y Wagner J A (2005) “Pharmacokinetics and pharmacodynamics of sitagliptin an inhibitor of dipeptidyl peptidase IV in in healthy subjects: results from two randomized double-blind placebo- controlled studies with single oral doses” En: Clinical Pharmacology and Therapeutics 78(6) 675–688 Consultado en: https://doi org/10 1016/j clpt 2005 09 002 Herman G A A A Bergman A A A Liu F Stevens C Wang A A A Q Zeng W Chen L Snyder K Hilliard D Tanen M Tanaka W Meehan A G Lasseter K Dilzer S Blum R y Wagner J A (2006) “Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in in middle-aged obese subjects” En: Journal of Clinical Pharmacology 46(8) 876–886 Consultado en: https://doi org/10 1177/0091270006289850
Heo Y A A (2022) “Sotrovimab: First Approval” En: Drugs 82(4) 477–484 Consultado en: https://doi org/10 1007/s40265- 022-01690-7
Holtzman C W W Wiggins B S S S y Spinler S S S A (2006) “Role of P-glycoprotein in in in in statin drug interactions” En: Pharmacotherapy 26(11) 1601–1607 Consultado en: https://doi org/10 1592/phco 26 11 1601 Hull M M W y Montaner J S (2011) “Ritonavir-boosted protease inhibitors in in in HIV therapy” En: Annals of Medicine 43(5) 375–388 Consultado en: https://doi org/10 3109/07853 890 2011 572905
Hung Y P P Lee Lee J J C C C C C Chiu C C C C C W Lee Lee C C C C C C C C C C Tsai P P J J Hsu I L L L y Ko W C (2022) “Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?” En: Antibiotics (Basel Switzerland) 11(2) 220 Consultado en: https:// doi org/10 3390/antibiotics11020220
Imran M M Kumar Arora M M Asdaq S S S Khan S S S A A A A Alaqel S S S I I Alshammari M M M M K Alshehri M M M M M M M M Alshrari A A A A S Mateq Ali A A A A A A Al-Shammeri A A A A A A M Alhazmi B D Harshan A A A A A A A A A Alam M T y y Abida (2021) “Discovery Development and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19” En: Molecules (Basel Switzerland) 26(19) 5795 Consultado en: https://doi org/10 3390/molecules26195795
IMSS Instituto Mexicano del Seguro Social (2018) “Diagnóstico y Tratamiento Farmacológico de la Diabetes Mellitus Tipo 2 en en el el Primer Nivel de de Atención” En: Guía de de Evidencias y Recomendaciones: Guía de de Práctica Clínica México Instituto Mexicano del Seguro Social Consultado en: http://www imss gob mx/sites/all/statics/ guiasclinicas/718GER pdf
INEGI Instituto Nacional de Estadística y Geografía (2021 octubre 28) Características de de las defunciones registradas en México durante 2020 Comunicado de prensa Núm 592/21 Consultado en: https://www inegi org mx/ contenidos/saladeprensa/boletines/2021/EstSociodemo/ DefuncionesRegistradas2020preliminar pdf
Infectious Disease Society of America IDSA IDSA (2022 junio 15) IDSA IDSA Guidelines on the Treatment and Management of Patients with COVID-19 Consultado en: https://www idsociety org/practice-guideline/covid-19-guideline- treatment-and-management/
Kabinger F Stiller C C Schmitzová J Dienemann C C Kokic G Hillen H H S Höbartner C C y Cramer P (2021) “Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis” En: Nature Structural y y Molecular Biology 28(9) 740–746 Consultado en: https://doi org/10 1038/s41594-021- 00651-0
Kahn C R (1985) “The molecular mechanism of insulin action” En: Annual Review of Medicine 36 429–451 Consultado en: https://doi org/10 1146/annurev me 36 020185 002241
Kaplon H Chenoweth A Crescioli S y Reichert J M (2022) “Antibodies to watch in 2022” En: mAbs 14(1) 2014296 Consultado en: https://doi org/10 1080/19420862 202 1 1 2014296 Kasichayanula S S Liu X Lacreta F Griffen S S C y y Boulton D W (2014) “Clinical pharmacokinetics and pharmacodynamics of of dapagliflozin a a a selective inhibitor of of sodium-glucose co-transporter type 2” En: Clinical Pharmacokinetics 53(1) 17–27 Consultado en: https://doi org/10 1007/ s40262-013-0104-3
Kaspera R Kirby B J Sahele T Collier A C C Kharasch E D Unadkat J D y Totah R A (2014) “Investigating the contribution of CYP2J2 to to ritonavir metabolism in vitro and in vivo” En: Biochemical Pharmacology 91(1) 109–118 Consultado en: https://doi org/10 1016/j bcp 2014 06 020 Kirchheiner J Roots I Goldammer M Rosenkranz B B y Brockmöller J (2005) “Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance” Consultado en: Clinical Pharmacokinetics 44(12) 1209–1225 Consultado en: https://doi org/10 2165/00003088-200544120-00002
Kohli R Shevitz A A Gorbach S S y Wanke C (2007) “A randomized placebo-controlled trial of metformin for for the treatment of HIV HIV lipodystrophy” En: HIV HIV Medicine 8(7) 420– 426 Consultado en: https://doi org/10 1111/j 1468- 1293 2007 00488 x
Lai C C C C C C C C C C C C Chen I I T Chao C C C C C C M Lee P P I I Ko W C C C C C C y Hsueh P P R (2021) “COVID-19 vaccines: concerns beyond protective efficacy and safety” En: Expert Review of Vaccines 20(8) 1013–1025 Consultado en: https://doi org/10 1080/1476 0584 2021 1949293
Lamb Y N N (2022) “Nirmatrelvir plus ritonavir: first approval” En: Drugs 82(5) 585–591 Consultado en: https://doi org/10 1007/s40265-022-01692-5
Lee G A A Lo J J C Aweeka F Schwarz J J M M Mulligan K Schambelan M y Grunfeld C (2006) “Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in in healthy volunteers” En: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 43(5) 658–660 Consultado en: https://doi org/10 1086/505974
INVESTIGACIÓN UNIVERSITARIA MULTIDISCIPLINARIA - - AÑO 21 21 No21 ENERO - - DICIEMBRE 2022 127